Savara Inc. Common Stock SVRA
i
Market datapartial · fetched 2026-11-04T09:59:04.507Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-04T09:05:08.966248342Z
FundamentalsAlpha Vantage · unavailable
Savara Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 4.08 | 180.6% | 23.6% | |||
| 30Δ | 4.37 | 207.8% | 22.7% | |||
| 35Δ | 7.73 | 295.0% | 69.7% | 4.66 | 234.9% | 21.8% |
| 40Δ | 7.06 | 270.0% | 57.0% | 4.95 | 262.1% | 20.9% |
| 45Δ | 6.39 | 245.1% | 44.3% | 6.18 | 399.6% | 25.0% |
| 50Δ | 5.72 | 220.1% | 31.5% | 6.42 | 365.1% | 21.0% |
| 55Δ | 5.05 | 195.1% | 18.8% | 6.67 | 330.7% | 17.0% |
| 60Δ | 6.91 | 296.3% | 13.0% | |||
| 65Δ | 7.22 | 274.2% | 10.2% | |||
| 70Δ | 7.57 | 259.5% | 8.0% | |||
| 75Δ | 7.92 | 244.8% | 5.9% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.08
- IV
- 180.6%
- B/E move
- 23.6%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.37
- IV
- 207.8%
- B/E move
- 22.7%
35Δ
- Pseudo strike
- 7.73
- IV
- 295.0%
- B/E move
- 69.7%
- Pseudo strike
- 4.66
- IV
- 234.9%
- B/E move
- 21.8%
40Δ
- Pseudo strike
- 7.06
- IV
- 270.0%
- B/E move
- 57.0%
- Pseudo strike
- 4.95
- IV
- 262.1%
- B/E move
- 20.9%
45Δ
- Pseudo strike
- 6.39
- IV
- 245.1%
- B/E move
- 44.3%
- Pseudo strike
- 6.18
- IV
- 399.6%
- B/E move
- 25.0%
50Δ
- Pseudo strike
- 5.72
- IV
- 220.1%
- B/E move
- 31.5%
- Pseudo strike
- 6.42
- IV
- 365.1%
- B/E move
- 21.0%
55Δ
- Pseudo strike
- 5.05
- IV
- 195.1%
- B/E move
- 18.8%
- Pseudo strike
- 6.67
- IV
- 330.7%
- B/E move
- 17.0%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.91
- IV
- 296.3%
- B/E move
- 13.0%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.22
- IV
- 274.2%
- B/E move
- 10.2%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.57
- IV
- 259.5%
- B/E move
- 8.0%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.92
- IV
- 244.8%
- B/E move
- 5.9%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 185.27% |
Biotechnology
SYRE
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody…
More →TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment of cancer and rare…
More →TARS
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions.…
More →TECH
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the global clinical diagnostic and research markets. The company is…
More →TECX
Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel therapies for patients…
More →TENX
Description unavailable
More →